119 related articles for article (PubMed ID: 33721455)
1. The expression of growth differentiation factor 15 in gallbladder carcinoma.
Yan Y; Yue X; Yang S; Zhao Z; Wu P; Liu H
J BUON; 2021; 26(1):218-228. PubMed ID: 33721455
[TBL] [Abstract][Full Text] [Related]
2. Expression of CDC6 and GDF-9 and their clinicopathological significances in benign and malignant lesions of the gallbladder.
Shu GS; Yang LP; Yang ZL; Jiang S
Cancer Biomark; 2012; 11(2-3):107-14. PubMed ID: 23011157
[TBL] [Abstract][Full Text] [Related]
3. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
Engerud H; Hope K; Berg HF; Fasmer KE; Tangen IL; Haldorsen IS; Trovik J; Krakstad C
PLoS One; 2019; 14(1):e0210585. PubMed ID: 30645608
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions.
Bock AJ; Stavnes HT; Kempf T; Tropè CG; Berner A; Davidson B; Staff AC
Int J Gynecol Cancer; 2010 Dec; 20(9):1448-55. PubMed ID: 21336029
[TBL] [Abstract][Full Text] [Related]
5. GDF 15 as an anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma.
Schiegnitz E; Kämmerer PW; Koch FP; Krüger M; Berres M; Al-Nawas B
Oral Oncol; 2012 Jul; 48(7):608-14. PubMed ID: 22341306
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder.
Zou Q; Xiong L; Yang Z; Lv F; Yang L; Miao X
World J Surg Oncol; 2012 May; 10():92. PubMed ID: 22613496
[TBL] [Abstract][Full Text] [Related]
7. GDF-15: a novel serum marker for metastases in uveal melanoma patients.
Suesskind D; Schatz A; Schnichels S; Coupland SE; Lake SL; Wissinger B; Bartz-Schmidt KU; Henke-Fahle S
Graefes Arch Clin Exp Ophthalmol; 2012 Jun; 250(6):887-95. PubMed ID: 21881845
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
Staff AC; Bock AJ; Becker C; Kempf T; Wollert KC; Davidson B
Gynecol Oncol; 2010 Sep; 118(3):237-43. PubMed ID: 20576287
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
Staff AC; Trovik J; Eriksson AG; Wik E; Wollert KC; Kempf T; Salvesen HB
Clin Cancer Res; 2011 Jul; 17(14):4825-33. PubMed ID: 21616994
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Correlation between Growth Differentiation Factor 15 Serum Level and Its Gene Expression with Psoriasis and Its Severity.
Akbari H; Talaee R; Zaker SF; Nikoueinejad H
Iran J Allergy Asthma Immunol; 2021 Sep; 20(5):593-599. PubMed ID: 34664818
[TBL] [Abstract][Full Text] [Related]
11. Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome.
Li QL; Yang ZL; Liu JQ; Miao XY
Pathol Oncol Res; 2011 Sep; 17(3):561-8. PubMed ID: 21221877
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
13. Research on values of GDF-15 level in the diagnosis of primary liver cancer and evaluation of chemotherapeutic effect.
Shen Y; Zhang ZB; Wu SD; Wu XB; Li J
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3749-3754. PubMed ID: 29949149
[TBL] [Abstract][Full Text] [Related]
14. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
[TBL] [Abstract][Full Text] [Related]
15. [Expression of P62 in gallbladder carcinoma tissues and its correlation with angiogenesis].
Wang J; Dou KF; Zhao R
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jul; 20(4):461-4. PubMed ID: 15207094
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between serum growth differentiation factor-15 and TIMI risk scores in patients with unstable angina pectoris].
Deng MY; Wu GP; Feng XX; Luo JB
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1277-8. PubMed ID: 21764714
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
[TBL] [Abstract][Full Text] [Related]
18. Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Xiong L; Deng X; Wen Y; Yang Z; Miao X
World J Surg Oncol; 2013 Mar; 11():80. PubMed ID: 23531103
[TBL] [Abstract][Full Text] [Related]
19. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Li Q; Yang Z
J Exp Clin Cancer Res; 2009 May; 28(1):65. PubMed ID: 19445727
[TBL] [Abstract][Full Text] [Related]
20. Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer.
Vocka M; Langer D; Fryba V; Petrtyl J; Hanus T; Kalousova M; Zima T; Petruzelka L
Cancer Biomark; 2018; 21(4):869-874. PubMed ID: 29400662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
